RecruitingPhase 3Device studyA Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMDThe purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.